NovoCure Ltd

NVCR

Explore Our Financial Data > Companies > NovoCure Ltd
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NVCR
CIK0001645113
SIC3841
SectorManufacturing
Industry CategoryMedical Equipment
Industry GroupSurgical, Medical, And Dental Instruments And Supplies

Contact

AddressNO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Y9, JE2 4UF
Website novocure.com
Phone44 (0)15 3475 6700
CEOAsaf Danziger
Employees1,320

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$621.71 million
Pre-Tax Income$-129.82 million
Net Income$-164.19 million
Net Income to Common$-164.19 million
EPS$-1.51
View All
Balance Sheet
Cash$127.28 million
Assets$1.25 billion
Liabilities$886.85 million
Common Equity$361.96 million
Liabilities & Equity$1.25 billion
View All
Cash Flow Statement
Net Income$-164.19 million
Cash From Operating Activities$-30.46 million
Cash From Investing Activities$-392.93 million
Cash From Financing Activities$95.35 million
Change in Cash$-327.93 million
View All
Calculations
NOPAT$-116.79 million
EBITDA$-182.01 million
Price to EarningsN/A
Price to Book$5.39
ROE-45.52%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

BAAR, Switzerland, July 01, 2025--Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, taking place July 2 to July 5 in Barcelona, Spain.

Article Link

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...

Article Link

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Article Link

Novocure to Report Second Quarter 2025 Financial Results

BAAR, Switzerland, June 30, 2025--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.

Article Link

What Makes NovoCure (NVCR) a New Buy Stock

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Article Link